Literature DB >> 10450803

Regeneration in sarcoglycanopathies: expression studies of sarcoglycans and other muscle proteins.

M Fanin1, C Angelini.   

Abstract

We have studied the immunohistochemical expression of 14 different muscle proteins of the basal lamina, sarcolemma and cytoskeleton in primary sarcoglycanopathies (13 cases) and compared it with Duchenne dystrophy (6 cases) and myositis (5 cases). Sarcolemmal proteins (i.e. 4 sarcoglycans, beta-dystroglycan, dystrophin, beta-spectrin) were reduced both in sarcoglycanopathies and Duchenne dystrophy, because of structural and functional impairment of the plasma membrane. Sarcolemmal proteins are poorly expressed in regenerating fibers of all muscle disorders, due to a developmental delay or to an abnormal assembly. Laminins (alpha2 and beta chains) were preserved in all cases while utrophin was expressed in Duchenne muscle but not in sarcoglycanopathies. Regenerating fibers were studied with different markers (i.e. fetal myosin, desmin, vimentin, laminin alpha1). Fetal myosin positive fibers (as well as desmin and laminin alpha1), were significantly higher in Duchenne dystrophy (25%) than in age-matched sarcoglycanopathies (7%). Vimentin, a marker of early regeneration, was expressed at higher level in sarcoglycanopathies than in Duchenne dystrophy, suggesting in the former a lower extent of regeneration or a shorter regeneration cycle.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10450803     DOI: 10.1016/s0022-510x(99)00102-1

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  3 in total

1.  Correlations between clinical severity, genotype and muscle pathology in limb girdle muscular dystrophy type 2A.

Authors:  M Fanin; L Nardetto; A C Nascimbeni; E Tasca; M Spinazzi; R Padoan; C Angelini
Journal:  J Med Genet       Date:  2007-05-25       Impact factor: 6.318

Review 2.  Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects.

Authors:  Dorianna Sandonà; Romeo Betto
Journal:  Expert Rev Mol Med       Date:  2009-09-28       Impact factor: 5.600

3.  P2X7 Receptor Antagonist Reduces Fibrosis and Inflammation in a Mouse Model of Alpha-Sarcoglycan Muscular Dystrophy.

Authors:  Lizzia Raffaghello; Elisa Principi; Serena Baratto; Chiara Panicucci; Sara Pintus; Francesca Antonini; Genny Del Zotto; Andrea Benzi; Santina Bruzzone; Paolo Scudieri; Carlo Minetti; Elisabetta Gazzerro; Claudio Bruno
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.